The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: Potential effects of exercise

Obesity Reviews

Volumn 16, Issue 6, 2015, Pages 473-487

  Schmidt, S ^a   Monk, J M ^b   Robinson, L E ^b   Mourtzakis, M ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

Author keywords

Adipokines; Body composition; Energy expenditure; IGF 1

Indexed keywords

ESTROGEN; INSULIN; LEPTIN; LEPTIN RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; ENERGY EXPENDITURE; EXERCISE; HORMONE METABOLISM; HORMONE RECEPTOR INTERACTION; HUMAN; OBESITY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BIOLOGICAL MODEL; BLOOD; BREAST NEOPLASMS; ENERGY METABOLISM; FEMALE; METABOLISM; MOLECULAR GENETICS; PATHOPHYSIOLOGY; RISK FACTOR; SECRETION (PROCESS);

ADIPOSITY; ANIMALS; BREAST NEOPLASMS; ENERGY METABOLISM; ESTROGENS; EXERCISE; FEMALE; HUMANS; INSULIN; LEPTIN; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84929131943     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12281     Document Type: Article

References (211)

1. (IRAC) IAfRoC. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide. 2012.
2. Danaei G, Vander Hoorn S, Lopez AD etal. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005; 366: 1784-1793.
3. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006; 13: 279-292.
4. Munoz-de-Toro M, Durando M, Beldomenico PM etal. Estrogenic microenvironment generated by organochlorine residues in adipose mammary tissue modulates biomarker expression in ERalpha-positive breast carcinomas. Breast Cancer Res 2006; 8: R47.
5. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355.
6. Han C, Zhang HT, Du L etal. Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine 2005; 26: 19-24.
7. Han CZ, Du LL, Jing JX etal. Associations among lipids, leptin, and leptin receptor gene Gin223Arg polymorphisms and breast cancer in China. Biol Trace Elem Res 2008; 126: 38-48.
8. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010; 119: 367-377.
9. Maccio A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes Rev 2009; 10: 660-670.
10. Ozet A, Arpaci F, Yilmaz MI etal. Effects of tamoxifen on the serum leptin level in patients with breast cancer. Jpn J Clin Oncol 2001; 31: 424-427.
11. Niu J, Jiang L, Guo W, Shao L, Liu Y, Wang L. The association between leptin level and breast cancer: a meta-analysis. PLoS ONE 2013; 8: e67349.
12. Jarde T, Caldefie-Chezet F, Damez M etal. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep 2008; 19: 905-911.
13. Zheng Q, Dunlap SM, Zhu J etal. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer 2011; 18: 491-503.
14. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2002; 293: 622-628.
15. Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibovich SJ. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 2010; 22: 1350-1362.
16. Knight BB, Oprea-Ilies GM, Nagalingam A etal. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer 2011; 18: 413-428.
17. Saxena NK, Vertino PM, Anania FA, Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 2007; 282: 13316-13325.
18. Grossmann ME, Cleary MP. The balance between leptin and adiponectin in the control of carcinogenesis - focus on mammary tumorigenesis. Biochimie 2012; 94: 2164-2171.
19. Jarde T, Caldefie-Chezet F, Goncalves-Mendes N etal. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009; 16: 1197-1210.
20. Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol 2008; 285: 43-50.
21. Taliaferro-Smith L, Nagalingam A, Knight BB, Oberlick E, Saxena NK, Sharma D. Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis. Neoplasia 2013; 15: 23-38.
22. Hou WK, Xu YX, Yu T etal. Adipocytokines and breast cancer risk. Chin Med J 2007; 120: 1592-1596.
23. Sharma D, Wang J, Fu PP etal. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010; 52: 1713-1722.
24. Jarde T, Perrier S, Vasson MP, Caldefie-Chezet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2011; 47: 33-43.
25. Irwin ML, McTiernan A, Bernstein L etal. Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors. Cancer Epidemiol Biomarkers Prev 2005; 14: 2881-2888.
26. Liuzzi A, Savia G, Tagliaferri M etal. Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. Int J Obes Relat Metab Disord 1999; 23: 1066-1073.
27. Magni P, Liuzzi A, Ruscica M etal. Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference. Clin Endocrinol (Oxf) 2005; 62: 189-196.
28. Rene Gonzalez R, Watters A, Xu Y etal. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009; 11: R36.
29. Saxena NK, Taliaferro-Smith L, Knight BB etal. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008; 68: 9712-9722.
30. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
31. Hamilton BS, Paglia D, Kwan AY, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995; 1: 953-956.
32. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-437.
33. Masuzaki H, Ogawa Y, Sagawa N etal. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 1997; 3: 1029-1033.
34. Bado A, Levasseur S, Attoub S etal. The stomach is a source of leptin. Nature 1998; 394: 790-793.
35. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 1998; 393: 684-688.
36. Smith-Kirwin SM, O'Connor DM, De Johnston J, Lancey ED, Hassink SG, Funanage VL. Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab 1998; 83: 1810-1813.
37. Maffei M, Halaas J, Ravussin E etal. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-1161.
38. Considine RV, Sinha MK, Heiman ML etal. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
39. Thomas T, Burguera B, Melton LJ III etal. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism 2000; 49: 1278-1284.
40. Knobelspies H, Zeidler J, Hekerman P, Bamberg-Lemper S, Becker W. Mechanism of attenuation of leptin signaling under chronic ligand stimulation. BMC Biochem 2010; 11: 2.
41. Munzberg H, Flier JS, Bjorbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 2004; 145: 4880-4889.
42. Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav 2014; 130: 157-169.
43. Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev 2013; 24: 503-513.
44. Carter S, Caron A, Richard D, Picard F. Role of leptin resistance in the development of obesity in older patients. Clin Interv Aging 2013; 8: 829-844.
45. Saad MF, Damani S, Gingerich RL etal. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997; 82: 579-584.
46. Carmina E, Ferin M, Gonzalez F, Lobo RA. Evidence that insulin and androgens may participate in the regulation of serum leptin levels in women. Fertil Steril 1999; 72: 926-931.
47. Hislop MS, Ratanjee BD, Soule SG, Marais AD. Effects of anabolic-androgenic steroid use or gonadal testosterone suppression on serum leptin concentration in men. Eur J Endocrinol 1999; 141: 40-46.
48. Rosenbaum M, Pietrobelli A, Vasselli JR, Heymsfield SB, Leibel RL. Sexual dimorphism in circulating leptin concentrations is not accounted for by differences in adipose tissue distribution. Int J Obes Relat Metab Disord 2001; 25: 1365-1371.
49. Banks WA. The many lives of leptin. Peptides 2004; 25: 331-338.
50. Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 2004; 59: 305-331.
51. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997; 272: 32686-32695.
52. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26: 1407-1433.
53. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272: 6093-6096.
54. Tartaglia LA, Dembski M, Weng X etal. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-1271.
55. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006; 393: 7-20.
56. Schulz LC, Widmaier EP. Leptin receptors. In: Castracane MC, Henson VD (eds). Lepin. Springer: New York, New York, 2007, pp. 12-31.
57. Hileman SM, Tornoe J, Flier JS, Bjorbaek C. Transcellular transport of leptin by the short leptin receptor isoform ObRa in Madin-Darby canine kidney cells. Endocrinology 2000; 141: 1955-1961.
58. Murakami T, Yamashita T, Iida M, Kuwajima M, Shima K. A short form of leptin receptor performs signal transduction. Biochem Biophys Res Commun 1997; 231: 26-29.
59. Dubois V, Jarde T, Delort L etal. Leptin induces a proliferative response in breast cancer cells but not in normal breast cells. Nutr Cancer 2014; 66: 645-655.
60. Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun 2001; 283: 982-988.
61. Zhang J, Scarpace PJ. The soluble leptin receptor neutralizes leptin-mediated STAT3 signalling and anorexic responses in vivo. Br J Pharmacol 2009; 158: 475-482.
62. Brabant G, Nave H, Mayr B, Behrend M, van Harmelen V, Arner P. Secretion of free and protein-bound leptin from subcutaneous adipose tissue of lean and obese women. J Clin Endocrinol Metab 2002; 87: 3966-3970.
63. Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers 2014; 6: 897-925.
64. Timofeeva OA, Tarasova NI, Zhang X etal. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A 2013; 110: 1267-1272.
65. Brown KA, Simpson ER. Obesity and breast cancer: progress to understanding the relationship. Cancer Res 2010; 70: 4-7.
66. Frankenberry KA, Skinner H, Somasundar P, McFadden DW, Vona-Davis LC. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 2006; 28: 985-993.
67. Normanno N, De Luca A, Maiello MR etal. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006; 207: 420-427.
68. Mantzoros CS, Magkos F, Brinkoetter M etal. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011; 301: E567-E584.
69. Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause 2006; 13: 280-285.
70. Hadji P, Bock K, Gotschalk M etal. The influence of serum leptin concentration on bone mass assessed by quantitative ultrasonometry in pre and postmenopausal women. Maturitas 2003; 44: 141-148.
71. Lee CG, Carr MC, Murdoch SJ etal. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 2009; 94: 1104-1110.
72. Sieminska L, Wojciechowska C, Foltyn W etal. The relation of serum adiponectin and leptin levels to metabolic syndrome in women before and after the menopause. Endokrynol Pol 2006; 57: 15-22.
73. Cleary MP, Grossmann ME. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 2009; 150: 2537-2542.
74. Biglia N, Peano E, Sgandurra P etal. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol 2013; 29: 263-267.
75. Garrisi VM, Tufaro A, Trerotoli P etal. Body mass index and serum proteomic profile in breast cancer and healthy women: a prospective study. PLoS ONE 2012; 7: e49631.
76. Kamineni A, Anderson ML, White E etal. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control 2013; 24: 305-312.
77. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009; 18: 2569-2578.
78. Bell KE, Di Sebastiano KM, Vance V etal. A comprehensive metabolic evaluation reveals impaired glucose metabolism and dyslipidemia in breast cancer patients early in the disease trajectory. Clin Nutr 2014; 33: 550-557.
79. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997; 8: 922-928.
80. Hankinson SE, Willett WC, Manson JE etal. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998; 90: 1292-1299.
81. Sonnenschein E, Toniolo P, Terry MB etal. Body fat distribution and obesity in pre- and postmenopausal breast cancer. Int J Epidemiol 1999; 28: 1026-1031.
82. Ollberding NJ, Kim Y, Shvetsov YB etal. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res 2013; 6: 188-195.
83. Chen DC, Chung YF, Yeh YT etal. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006; 237: 109-114.
84. Miyoshi Y, Funahashi T, Tanaka S etal. High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer 2006; 118: 1414-1419.
85. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004; 10: 4325-4331.
86. Cleary MP, Phillips FC, Getzin SC etal. Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 2003; 77: 205-215.
87. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, Maihle NJ. Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med 2004; 229: 182-193.
88. Garofalo C, Koda M, Cascio S etal. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 2006; 12: 1447-1453.
89. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J. Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 2002; 188: 219-226.
90. Fiorio E, Mercanti A, Terrasi M etal. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008; 8: 305.
91. Otvos L Jr, Kovalszky I, Riolfi M etal. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer 2011; 47: 1578-1584.
92. Otvos L Jr, Surmacz E. Targeting the leptin receptor: a potential new mode of treatment for breast cancer. Expert Rev Anticancer Ther 2011; 11: 1147-1150.
93. Guo S, Gonzalez-Perez RR. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLoS ONE 2011; 6: e21467.
94. Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer 2011; 104: 128-137.
95. Koda M, Sulkowska M, Kanczuga-Koda L, Jarzabek K, Sulkowski S. Expression of leptin and its receptor in female breast cancer in relation with selected apoptotic markers. Folia Histochem Cytobiol 2007; 45(Suppl. 1): S187-S191.
96. Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP. Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 2009; 21: 1611-1619.
97. Perera CN, Chin HG, Duru N, Camarillo IG. Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression. J Endocrinol 2008; 199: 221-233.
98. Morad V, Abrahamsson A, Dabrosin C. Estradiol affects extracellular leptin:adiponectin ratio in human breast tissue in vivo. J Clin Endocrinol Metab 2014; 99: 3460-3467.
99. Ray A. Adipokine leptin in obesity-related pathology of breast cancer. J Biosci 2012; 37: 289-294.
100. Saxena NK, Sharma D. Multifaceted leptin network: the molecular connection between obesity and breast cancer. J Mammary Gland Biol Neoplasia 2013; 18: 309-320.
101. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344: 276-285.
102. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282.
103. Yue W, Yager JD, Wang JP, Jupe ER, Santen RJ. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 2013; 78: 161-170.
104. Baglietto L, English DR, Hopper JL etal. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 2009; 115: 171-179.
105. Key T, Appleby P, Barnes I, Reeves G, Endogenous H, Breast Cancer Collaborative G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-616.
106. Key TJ, Appleby PN, Reeves GK etal. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218-1226.
107. Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol 2013; 75: 225-240.
108. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978; 130: 448-455.
109. Ferguson RD, Gallagher EJ, Scheinman EJ, Damouni R, LeRoith D. The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. Vitam Horm 2013; 93: 51-98.
110. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004; 5: 153-165.
111. Geisler J, Haynes B, Ekse D, Dowsett M, Lonning PE. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Steroid Biochem Mol Biol 2007; 104: 27-34.
112. Catalano S, Marsico S, Giordano C etal. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 2003; 278: 28668-28676.
113. Catalano S, Mauro L, Marsico S etal. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 2004; 279: 19908-19915.
114. Fusco R, Galgani M, Procaccini C etal. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer 2010; 17: 373-382.
115. Garofalo C, Sisci D, Surmacz E. Leptin interferes with the effects of the antiestrogen ICI 182, 780 in MCF-7 breast cancer cells. Clin Cancer Res 2004; 10: 6466-6475.
116. Chen X, Zha X, Chen W etal. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer. Biomed Pharmacother 2013; 67: 22-30.
117. Yom CK, Lee KM, Han W etal. Leptin as a potential target for estrogen receptor-positive breast cancer. J Breast Cancer 2013; 16: 138-145.
118. Binai NA, Damert A, Carra G etal. Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer 2010; 127: 55-66.
119. Liu E, Samad F, Mueller BM. Local adipocytes enable estrogen-dependent breast cancer growth: role of leptin and aromatase. Adipocyte 2013; 2: 165-169.
120. Boeing H. Obesity and cancer - the update 2013. Best Pract Res Clin Endocrinol Metab 2013; 27: 219-227.
121. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006; 296: 193-201.
122. Vague P, Juhan-Vague I, Aillaud MF etal. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253.
123. Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G. UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab 1997; 82: 654-657.
124. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-2117.
125. Schelbert KB. Comorbidities of obesity. Prim Care 2009; 36: 271-285.
126. Nam SY, Lee EJ, Kim KR etal. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 1997; 21: 355-359.
127. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328-336.
128. Frittitta L, Vigneri R, Papa V, Goldfine ID, Grasso G, Trischitta V. Structural and functional studies of insulin receptors in human breast cancer. Breast Cancer Res Treat 1993; 25: 73-82.
129. Belardi V, Gallagher EJ, Novosyadlyy R, LeRoith D. Insulin and IGFs in obesity-related breast cancer. J Mammary Gland Biol Neoplasia 2013; 18: 277-289.
130. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-518.
131. Hawsawi Y, El-Gendy R, Twelves C, Speirs V, Beattie J. Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis. Biochim Biophys Acta 2013; 1836: 345-353.
132. Bruning PF, Van Doorn J, Bonfrer JM etal. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995; 62: 266-270.
133. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010; 11: 530-542.
134. Peyrat JP, Bonneterre J, Hecquet B etal. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993; 29A: 492-497.
135. Goodwin PJ, Ennis M, Pritchard KI etal. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 2002; 74: 65-76.
136. Law JH, Habibi G, Hu K etal. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68: 10238-10246.
137. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001; 8: 197-209.
138. Ozbay T, Nahta R. A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells. Mol Cancer Res 2008; 6: 1052-1058.
139. Lueprasitsakul P, Latour D, Longcope C. Aromatase activity in human adipose tissue stromal cells: effect of growth factors. Steroids 1990; 55: 540-544.
140. Chong YM, Colston K, Jiang WG, Sharma AK, Mokbel K. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat 2006; 99: 275-288.
141. Pichard C, Plu-Bureau G, Neves ECM, Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas 2008; 60: 19-30.
142. Jones LW, Alfano CM. Exercise-oncology research: past, present, and future. Acta Oncol (Madr) 2013; 52: 195-215.
143. Halle M, Berg A, Garwers U, Grathwohl D, Knisel W, Keul J. Concurrent reductions of serum leptin and lipids during weight loss in obese men with type II diabetes. Am J Physiol 1999; 277: E277-E282.
144. Westerterp-Plantenga MS, Lejeune MP, Nijs I, van Ooijen M, Kovacs EM. High protein intake sustains weight maintenance after body weight loss in humans. Int J Obes Relat Metab Disord 2004; 28: 57-64.
145. Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol 1993; 11: 1418-1429.
146. Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 2002; 20: 3302-3316.
147. Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 2011; 12: 282-294.
148. Del Rio G, Zironi S, Valeriani L etal. Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition. Breast Cancer Res Treat 2002; 73: 267-273.
149. Caan BJ, Emond JA, Natarajan L etal. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat 2006; 99: 47-57.
150. Demark-Wahnefried W, Peterson BL, Winer EP etal. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2001; 19: 2381-2389.
151. Rock CL, Flatt SW, Newman V etal. Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. J Am Diet Assoc 1999; 99: 1212-1221.
152. Saquib N, Flatt SW, Natarajan L etal. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the Women's Healthy Eating and Living (WHEL) study. Breast Cancer Res Treat 2007; 105: 177-186.
153. Eliassen AH, Hankinson SE, Rosner B, Holmes MD, Willett WC. Physical activity and risk of breast cancer among postmenopausal women. Arch Intern Med 2010; 170: 1758-1764.
154. Friedenreich CM. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 2001; 10: 15-32.
155. Lee IM. Physical activity and cancer prevention - data from epidemiologic studies. Med Sci Sports Exerc 2003; 35: 1823-1827.
156. Irwin ML, Crumley D, McTiernan A etal. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer 2003; 97: 1746-1757.
157. Cheney CL, Mahloch J, Freeny P. Computerized tomography assessment of women with weight changes associated with adjuvant treatment for breast cancer. Am J Clin Nutr 1997; 66: 141-146.
158. Harvie MN, Campbell IT, Baildam A, Howell A. Energy balance in early breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2004; 83: 201-210.
159. Backman M, Wengstrom Y, Johansson B etal. A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer. Acta Oncol (Madr) 2014; 53: 510-520.
160. Bower JE, Greendale G, Crosswell AD etal. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. Psychoneuroendocrinology 2014; 43: 20-29.
161. Casla S, Hojman P, Cubedo R, Calvo I, Sampedro J, Barakat R. Integrative exercise and lifestyle intervention increases leisure-time activity in breast cancer patients. Integr Cancer Ther 2014; 13: 493-501.
162. Travier N, Fonseca-Nunes A, Javierre C etal. Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors. Med Oncol 2014; 31: 783.
163. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 2006; 175: 34-41.
164. Mishra SI, Scherer RW, Geigle PM etal. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev 2012; (8): CD007566.
165. Sturgeon KM, Ky B, Libonati JR, Schmitz KH. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer. Breast Cancer Res Treat 2014; 143: 219-226.
166. Brenner DR, Neildon HK, Courneya KS, Friedenreich CM. Physical activity after breast cancer: effect on survival and patient-reported outcomes. Curr Breast Cancer Rep 2014; 6: 193-204.
167. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104: 815-840.
168. Bertram LA, Stefanick ML, Saquib N etal. Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study. Cancer Causes Control 2011; 22: 427-435.
169. Chen X, Lu W, Zheng W etal. Exercise after diagnosis of breast cancer in association with survival. Cancer Prev Res 2011; 4: 1409-1418.
170. Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer 2011; 105(Suppl. 1): S52-S73.
171. Friedenreich CM. Physical activity and breast cancer: review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res 2011; 188: 125-139.
172. Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 2011; 28: 753-765.
173. Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol 2014; 25: 1293-1311.
174. Schmitz KH, Courneya KS, Matthews C etal. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42: 1409-1426.
175. Scott E, Daley AJ, Doll H etal. Effects of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis after early-stage breast cancer: a randomized controlled trial. Cancer Causes Control 2013; 24: 181-191.
176. Rogers LQ, Fogleman A, Trammell R etal. Effects of a physical activity behavior change intervention on inflammation and related health outcomes in breast cancer survivors: pilot randomized trial. Integr Cancer Ther 2013; 12: 323-335.
177. De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CH. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 2013; 100: 1421-1429.
178. Hayashino Y, Jackson JL, Hirata T etal. Effects of exercise on C-reactive protein, inflammatory cytokine and adipokine in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Metabolism 2014; 63: 431-440.
179. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-862.
180. Liao S, Li J, Wei W etal. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev 2011; 12: 1061-1065.
181. Bouassida A, Chamari K, Zaouali M, Feki Y, Zbidi A, Tabka Z. Review on leptin and adiponectin responses and adaptations to acute and chronic exercise. Br J Sports Med 2010; 44: 620-630.
182. Damaso AR, da Silveira Campos RM, Caranti DA etal. Aerobic plus resistance training was more effective in improving the visceral adiposity, metabolic profile and inflammatory markers than aerobic training in obese adolescents. J Sports Sci 2014; 32: 1435-1445.
183. Ishii T, Yamakita T, Yamagami K etal. Effect of exercise training on serum leptin levels in type 2 diabetic patients. Metabolism 2001; 50: 1136-1140.
184. Kurose S, Tsutsumi H, Yamanaka Y etal. Improvement in endothelial function by lifestyle modification focused on exercise training is associated with insulin resistance in obese patients. Obes Res Clin Pract 2014; 8: e106-e114.
185. Ahmadizad S, Haghighi AH, Hamedinia MR. Effects of resistance vs. endurance training on serum adiponectin and insulin resistance index. Eur J Endocrinol 2007; 157: 625-631.
186. Llanos AA, Krok JL, Peng J etal. Effects of a walking intervention using mobile technology and interactive voice response on serum adipokines among postmenopausal women at increased breast cancer risk. Horm Cancer 2014; 5: 98-103.
187. Botero JP, Shiguemoto GE, Prestes J etal. Effects of long-term periodized resistance training on body composition, leptin, resistin and muscle strength in elderly post-menopausal women. J Sports Med Phys Fitness 2013; 53: 289-294.
188. Hickey MS, Houmard JA, Considine RV etal. Gender-dependent effects of exercise training on serum leptin levels in humans. Am J Physiol 1997; 272: E562-E566.
189. Ordonez FJ, Fornieles-Gonzalez G, Camacho A etal. Anti-inflammatory effect of exercise, via reduced leptin levels, in obese women with Down syndrome. Int J Sport Nutr Exerc Metab 2013; 23: 239-244.
190. Reseland JE, Anderssen SA, Solvoll K etal. Effect of long-term changes in diet and exercise on plasma leptin concentrations. Am J Clin Nutr 2001; 73: 240-245.
191. Longcope C, Bourget C, Flood C. The production and aromatization of dehydroepiandrosterone in post-menopausal women. Maturitas 1982; 4: 325-332.
192. Friedenreich CM, Woolcott CG, McTiernan A etal. Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol 2010; 28: 1458-1466.
193. Janelsins MC, Davis PG, Wideman L etal. Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin Breast Cancer 2011; 11: 161-170.
194. Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974; 3: 69-96.
195. Campbell KL, Foster-Schubert KE, Alfano CM etal. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J Clin Oncol 2012; 30: 2314-2326.
196. McTiernan A, Tworoger SS, Ulrich CM etal. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res 2004; 64: 2923-2928.
197. Kim JW, Kim DY. Effects of aerobic exercise training on serum sex hormone binding globulin, body fat index, and metabolic syndrome factors in obese postmenopausal women. Metab Syndr Relat Disord 2012; 10: 452-457.
198. Rock CL, Pande C, Flatt SW etal. Favorable changes in serum estrogens and other biologic factors after weight loss in breast cancer survivors who are overweight or obese. Clin Breast Cancer 2013; 13: 188-195.
199. Neilson HK, Conroy SM, Friedenreich CM. The influence of energetic factors on biomarkers of postmenopausal breast cancer risk. Curr Nutr Rep 2014; 3: 22-34.
200. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 1996; 7: 605-625.
201. Pugeat M, Crave JC, Elmidani M etal. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol 1991; 40: 841-849.
202. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001; 60: 91-106.
203. Garcia-Hermoso A, Saavedra JM, Escalante Y, Sanchez-Lopez M, Martinez-Vizcaino V. Endocrinology and adolescence: aerobic exercise reduces insulin resistance markers in obese youth: a meta-analysis of randomized controlled trials. Eur J Endocrinol 2014; 171: R163-R171.
204. Trapp EG, Chisholm DJ, Freund J, Boutcher SH. The effects of high-intensity intermittent exercise training on fat loss and fasting insulin levels of young women. Int J Obes 2008; 32: 684-691.
205. Wieczorek-Baranowska A, Nowak A, Michalak E etal. Effect of aerobic exercise on insulin, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in overweight and obese postmenopausal women. J Sports Med Phys Fitness 2011; 51: 525-532.
206. Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2003; 12: 721-727.
207. Irwin ML, Varma K, Alvarez-Reeves M etal. Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomarkers Prev 2009; 18: 306-313.
208. Bustos S, Denegri JC, Diaz F, Tchernitchin AN. p, p′-DDT is an estrogenic compound. Bull Environ Contam Toxicol 1988; 41: 496-501.
209. Pelletier C, Imbeault P, Tremblay A. Energy balance and pollution by organochlorines and polychlorinated biphenyls. Obes Rev 2003; 4: 17-24.
210. Khanjani N, Hoving JL, Forbes AB, Sim MR. Systematic review and meta-analysis of cyclodiene insecticides and breast cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007; 25: 23-52.
211. Rusiecki JA, Matthews A, Sturgeon S etal. A correlation study of organochlorine levels in serum, breast adipose tissue, and gluteal adipose tissue among breast cancer cases in India. Cancer Epidemiol Biomarkers Prev 2005; 14: 1113-1124.